2017
DOI: 10.18632/oncotarget.23264
|View full text |Cite
|
Sign up to set email alerts
|

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

Abstract: In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cell lines more effectively than MPA treatment alone. Moreover, combined treatment with Gefitinib plus MPA reduced growth of EC xenografts in Balb/c nude mice more than either Gefitinib or MPA alone. The therapeutic ef… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 39 publications
0
5
0
Order By: Relevance
“…For this reason, obtaining an optimal progesterone transcription level is important and could set the stage for effective precision dual therapy with progestin and a tyrosine kinase inhibitor in endometrial cancer patients. This is an approach that, albeit not yet personalized, has started to attract attention and bear fruits 40 , 41 , while Systems biology methods could help find conditions to activate and protect enough PR from ubiquitination, promoting maximal transcription and allowing for progestin treatment.…”
Section: Resultsmentioning
confidence: 99%
“…For this reason, obtaining an optimal progesterone transcription level is important and could set the stage for effective precision dual therapy with progestin and a tyrosine kinase inhibitor in endometrial cancer patients. This is an approach that, albeit not yet personalized, has started to attract attention and bear fruits 40 , 41 , while Systems biology methods could help find conditions to activate and protect enough PR from ubiquitination, promoting maximal transcription and allowing for progestin treatment.…”
Section: Resultsmentioning
confidence: 99%
“…Progesterone treatment in the early stages of EC has a better therapeutic effect in improving the survival rate and reducing the risk of treatment. Patients with intermediate and advanced stages undergo surgery or chemotherapy combined with drugs such as gefitinib (27) and cisplatin (28); however, the prognosis is still poor (29). Therefore, the study of its pathological mechanism is urgent.…”
Section: Discussionmentioning
confidence: 99%
“…Total protein was extracted and quantified according to the manufacturer's instructions. Western blot assay was performed as described previously [18] anti -Cav1.3 polyclonal antibody (1:1000, Abcam, USA), cleaved caspase 3/caspase 3 (1:1000, Abcam, USA), cleaved PARP/PARP (1:1000, Abcam, USA) were used. Use ECL substrate to detect its expression.…”
Section: Western Blot Assaymentioning
confidence: 99%